ERS Genomics inks licensing agreement with Applied StemCell

By The Science Advisory Board staff writers

September 15, 2020 -- ERS Genomics said that it has signed a licensing agreement with Applied StemCell to commercialize CRISPR gene editing services and reagents.

Financial terms of the deal were not disclosed. ERS Genomics was formed to provide broad access to CRISPR/Cas9 intellectual property co-owned by Emmanuelle Charpentier, PhD.

Companies can obtain licenses to this technology for internal research and commercialization of research tools, kits, reagents, and genetically modified cell lines and organisms, ERS Genomics said.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?